A sickle cell screen is a blood test that detects sickle hemoglobin (HbS), and what every medical professional needs to know is this: the right test depends on the patient’s age and the clinical question. Newborn programs use hemoglobin separation methods that can distinguish disease from trait, while the quick solubility test only shows whether HbS is present. Every positive screen needs confirmation, and every result needs to be interpreted in context.
In my practice, the most common screening errors are not laboratory failures. They are interpretation errors: a solubility test taken as a diagnosis, a newborn result read without considering transfusion, or a trait result never communicated to the family.
Why Sickle Cell Screening Matters
Sickle cell disease (SCD) results from a single nucleotide change in the beta-globin gene (HBB) on chromosome 11. It produces hemoglobin S, which polymerizes when deoxygenated and forces cells into a rigid sickle shape. These cells block small vessels and are destroyed early.
Screening matters because the most dangerous complications, such as overwhelming bacterial infection and splenic sequestration, can strike in the first years of life. Identifying affected infants early allows penicillin prophylaxis, vaccination, parent education, and specialist follow-up to begin before the first crisis.
Who should be screened
- All newborns in regions with universal newborn screening programs.
- Pregnant women and prospective parents, particularly those of African, Mediterranean, Middle Eastern, Indian, or Caribbean ancestry.
- Patients with unexplained hemolytic anemia, pain crises, or suggestive findings on a blood film.
- Before surgery or anesthesia in patients of unknown status from high-prevalence backgrounds.
- Athletes and military recruits, where policies require knowledge of sickle cell trait status.
Screening Methods Compared
Sickle cell screening uses several techniques, each with a defined role and known limits.
| Method | What it shows | Main limitation |
|---|---|---|
| Solubility test | Presence of HbS (positive or negative) | Cannot separate trait from disease; unreliable in infants under about six months |
| Isoelectric focusing (IEF) | Separates hemoglobin variants; widely used in newborn programs | Needs confirmation of abnormal patterns |
| High-performance liquid chromatography (HPLC) | Identifies and quantifies HbA, HbS, HbF, HbA2, and other variants | Some variants share retention times |
| Hemoglobin electrophoresis | Separates variants by charge; classic confirmatory method | Some variants co-migrate with HbS |
| DNA analysis | Confirms genotype, including beta-thalassemia mutations | More costly; reserved for ambiguous cases and prenatal diagnosis |
Reading newborn results
Newborn reports list hemoglobins in order of quantity. Because newborns have mostly fetal hemoglobin, F comes first. FA is normal, FAS suggests trait, FS is consistent with HbSS or HbS/beta-zero thalassemia, FSC indicates HbSC disease, and FSA suggests HbS/beta-plus thalassemia. An FS pattern needs repeat testing and family studies to separate HbSS from HbS/beta-zero thalassemia.
Premature infants and babies who received transfusion before sampling are a particular challenge. Programs usually request a repeat sample, and clinicians should never assume a normal newborn result rules out a hemoglobinopathy if the clinical picture later suggests one.
Screening in pregnancy and before conception
Antenatal screening aims to identify carrier couples early enough to offer informed choices. The usual approach is to test the pregnant woman first with a blood count and hemoglobin separation. If she carries HbS or another significant variant, her partner is offered testing. When both partners are carriers, genetic counseling and, if the couple wishes, prenatal diagnosis by DNA testing of fetal cells can follow. A low mean corpuscular volume in either partner should also raise the question of beta-thalassemia trait, which matters when combined with HbS.
Common Pitfalls in Interpretation
- Relying on a solubility test alone: a positive result means HbS is present, not that the patient has SCD. Hemoglobin separation is always required.
- Testing infants with high HbF: fetal hemoglobin dilutes HbS, so the solubility test can be falsely negative.
- Recent transfusion: donor red blood cells can mask or mimic patterns for about three months. Note transfusion history on the request.
- Severe anemia: very low hemoglobin can produce false-negative solubility results.
- Co-inherited thalassemia: the proportion of HbS in a trait carrier is normally below that of HbA. An unexpectedly low or high percentage should prompt further workup.
Clinical Picture After a Positive Screen
The screen itself does not measure severity, but a confirmed diagnosis should prompt anticipatory care. Symptoms usually appear in the second half of the first year as HbF declines.
- Dactylitis: painful swelling of the hands and feet, often the first sign in infants.
- Pain crises, anemia, and jaundice.
- Splenic sequestration and serious infections due to early splenic dysfunction.
- Acute chest syndrome and stroke.
- Later chronic complications, including pulmonary hypertension, kidney disease, and retinopathy.
Management After Diagnosis
Once confirmed, infants should be referred to a specialist hematology service. Core management includes:
- Penicillin prophylaxis from early infancy, with a complete vaccination schedule including pneumococcal vaccines.
- Hydroxyurea, which raises fetal hemoglobin and reduces pain crises and acute chest syndrome; it is now offered from early childhood.
- Transcranial Doppler screening in children with HbSS or HbS/beta-zero thalassemia, with transfusion for those at high stroke risk.
- Folic acid where indicated, and prompt pain management during crises.
- Curative options: bone marrow or stem cell transplantation, best results with a matched sibling donor, and gene-based therapies now approved in some countries.
Carriers identified by screening need something different: clear counseling that trait is not disease, information about reproductive risk, and practical advice about hydration and extreme exertion. See our sickle cell guide for patient-facing explanations.
Key Takeaways
- A sickle cell screen detects HbS; the method determines whether trait and disease can be distinguished.
- Solubility tests are screening tools only and are unreliable in young infants.
- Confirm every positive result with HPLC, electrophoresis, or DNA testing, and always record transfusion history.
- Early diagnosis enables penicillin, vaccination, hydroxyurea, and stroke screening, which change outcomes.
- Communicate trait results to families and offer genetic counseling.
Frequently Asked Questions
Can a sickle cell screen tell trait from disease?
It depends on the test. A solubility test cannot, because it only detects whether HbS is present. Hemoglobin separation methods such as HPLC, isoelectric focusing, and electrophoresis show the relative amounts of each hemoglobin and can distinguish trait from disease.
Why is the solubility test not used for newborns?
Newborns have mostly fetal hemoglobin, so the amount of HbS may be too low for the test to detect. This leads to false-negative results. Newborn programs use IEF or HPLC instead.
How long after a transfusion should screening wait?
Transfused red cells circulate for roughly three months, so results within that window may reflect donor blood. If testing cannot wait, DNA analysis gives a reliable genotype regardless of transfusion.
Should adults be screened if they were never tested as babies?
Yes, when there is a reason: family planning, pregnancy, unexplained anemia, planned surgery, or ancestry from a high-prevalence region. Many adults with the trait have never been told their status. A single hemoglobin separation test answers the question.
